PARP inhibitor

Apr 17, 2018

Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

Apr 16, 2018

DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research

Mar 22, 2018

Data on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting

Mar 14, 2018

Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

Mar 08, 2018

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases

Feb 21, 2018

Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

Nov 02, 2017

Epic Sciences Launches Single-Cell Microsatellite and Chromosomal Instability Genomic Analysis

Oct 25, 2017

Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

Oct 11, 2017

Sierra Oncology to Present at the 2017 BIO Investor Forum

Sep 27, 2017

DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

Sep 14, 2017

Sierra Oncology to Host KOL Call with Dr. Thomas Helleday presenting "DNA Damage Response (DDR) Targets Beyond PARP"

Jun 05, 2017

Caris Life Sciences' Molecular Intelligence Platform Measures Prevalence of Oncogenic Homologous Recombination Pathway Mutations across 53,000 Tumors